Edgar Filing: Miller Vincent A. - Form 4

Form 4 October 04, 2												
	_								OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB	3235-0287			
if no long	Washington, D.C. 20549 Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP						NERSHIP OF	Number: Jan Expires:	January 31 2005			
subject to Section 16. Form 4 or Form 5 obligations may continue. STATEMENT OF CHANGES I SEC Filed pursuant to Section 16(a) of Section 17(a) of the Public Utility F					of the Securities Exchange Act of 1934, Holding Company Act of 1935 or Section ment Company Act of 1940					Estimated average burden hours per response 0.5 n		
(Print or Type I	Responses)											
1. Name and Address of Reporting Person <u>*</u> Miller Vincent A.			2. Issuer Name and Ticker or Trading Symbol Foundation Medicine, Inc. [FMI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Middle)	3. Date of Earliest Transaction (Ch						.k all applicable)			
	ID STREET, C/0 ION MEDICINI		(Month/D 10/02/20	-				Director X Officer (give below) Chief		6 Owner er (specify er		
			4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
	GE, MA 02141							Person				
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ities Aco	quired, Disposed of	, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year) Execution any	med on Date, if Day/Year)	3. Transactio Code (Instr. 8)			d of	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
~				Code V	Amount		Price \$	(Instr. 3 and 4)				
Common Stock	10/02/2017			S	325 <u>(1)</u>	D	38.8 (2)	122,603 <u>(3)</u>	D			
Common Stock	10/02/2017			S	1,625 (4)	D	\$ 38.8 (5)	120,978 <u>(6)</u>	D			
Common Stock	10/02/2017			S	994 <u>(4)</u>	D	\$ 38.8	119,984 <u>(7)</u>	D			

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationship				
	Director	10% Owner	Officer		
ller Vincent A.					

Mil **150 SECOND STREET** C/O FOUNDATION MEDICINE, INC. CAMBRIDGE, MA 02141

Signatures

Robert W. Hesslein, as Attorney-in-Fact for Vincent A. Miller

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on September 30, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to (1) require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.

The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$38.48 to \$38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the

(2) Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

(3)

10/04/2017

Date

Chief Medical Officer

Other

Edgar Filing: Miller Vincent A. - Form 4

The reporting person previously reported all restricted stock units granted to the reporting person on April 9, 2014 in Table I of the Form 4/A filed on May 27, 2014. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect this vesting event.

Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm

(4) require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.

(5) The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$38.46 to \$38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 (6) filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale.

The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form (7) 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.